Posttransplantation Lymphoproliferative Disorder in Patients Under Primary Tacrolimus (FK 506) Immunosuppression
- 1 September 1995
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 121 (9) , 1037-1041
- https://doi.org/10.1001/archotol.1995.01890090073014
Abstract
Posttransplantation lymphoproliferative disorder (PTLD) is a well-described complication of the systemic immunosuppression required for successful organ transplantation. Lesions of PTLD often occur in the region of the head and neck and require otolaryngologic evaluations. Although the majority of reported cases of PTLD are associated with cyclosporine immunosuppression, recently, PTLD has been described in patients treated solely with the newer systemic immunosuppressive agent tacrolimus (FK 506). As an introduction to tacrolimus and to PTLD as one of its complications, a case of PTLD presenting as airway obstruction in a child treated solely with tacrolimus immunosuppression is described. In addition, a review of tacrolimus and PTLD in patients under tacrolimus immunosuppression is presented to familiarize the otolaryngologist with this important new immunosuppressive agent and a potential complication of its use. (Arch Otolaryngol Head Neck Surg 1995;121:1037-1041)Keywords
This publication has 7 references indexed in Scilit:
- Immunosuppressants at workNature, 1991
- Lymphoproliferative disorder in a liver transplant patient on FK 506The Lancet, 1991
- Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cellsThe Lancet, 1991
- Chemistry and Biology of the Immunophilins and Their Immunosuppressive LigandsScience, 1991
- Effects of a novel immunosuppressive agent, FK506, on human B cell activationClinical and Experimental Immunology, 1990
- FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATIONThe Lancet, 1989
- EPSTEIN-BARR VIRUS, IMMUNODEFICIENCY, AND B CELL LYMPHOPROLIFERATIONTransplantation, 1985